SYMLIN Drug Patent Profile

Which patents cover Symlin, and what generic alternatives are available?

Symlin is a drug marketed by Astrazeneca Ab and is included in one NDA.

The generic ingredient in SYMLIN is pramlintide acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pramlintide acetate profile page.

Summary for SYMLIN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	11
Clinical Trials:	20
Patent Applications:	2,325
Drug Prices:	Drug price information for SYMLIN
DailyMed Link:	SYMLIN at DailyMed

See drug prices for SYMLIN

Recent Clinical Trials for SYMLIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Aging (NIA)	Early Phase 1
Boston University	Early Phase 1
H. Lee Moffitt Cancer Center and Research Institute	Early Phase 1

See all SYMLIN clinical trials

Pharmacology for SYMLIN

Drug Class	Amylin Analog
Mechanism of Action	Amylin Agonists

US Patents and Regulatory Information for SYMLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007		RX	Yes	No
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007		RX	Yes	Yes
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005		DISCN	No	No

Expired US Patents for SYMLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007

International Patents for SYMLIN

See the table below for patents covering SYMLIN around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	T73490
Japan	H05505625
Germany	69227347
Canada	2082928	METHODES ET COMPOSITIONS POUR LE TRAITEMENT DU DIABETE SUCRE, DE L'HYPOGLYCEMIE ET D'AUTRES TROUBLES (METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES MELLITUS, HYPOGLYCEMIA, AND OTHER CONDITIONS)
Slovakia	88793	AMYLIN AGONISING PEPTIDES AND THEIR USING
Japan	H11152299	NEW AMYLIN AGONIST PEPTIDE AND ITS USE
Japan	H06510754

SYMLIN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Symlin (Pramlintide)

Introduction

Symlin (pramlintide) is an injectable medication used to manage blood sugar levels in patients with type 1 and type 2 diabetes. Developed by AstraZeneca, this drug has been a significant player in the diabetes management market. Here, we will delve into the market dynamics and financial trajectory of Symlin.

Market Size and Growth

The global Symlin (pramlintide) market has been experiencing substantial growth over the past few years. The market is estimated to continue growing significantly from 2024 to 2031, driven by increasing demand for effective diabetes management solutions[1][4].

Segmentation

The Symlin market is segmented based on application (Type I Diabetes, Type II Diabetes) and product type (1.5ml Pen-injector, 2.7ml Pen-injector). Additionally, the market is analyzed across various geographical regions including North America, Europe, Asia-Pacific, South America, and the Middle East and Africa[1].

Key Factors Affecting the Market

Several factors influence the Symlin market:

Increasing Prevalence of Diabetes

The rising global prevalence of diabetes, particularly type 2 diabetes, is a major driver for the Symlin market. As the number of diabetic patients increases, so does the demand for effective management solutions like Symlin[4].

Regulatory Approvals and Compliance

Regulatory approvals and compliance play a crucial role in the market dynamics. Any changes in regulatory requirements or approvals can significantly impact the market growth and revenue[3].

Technological Advancements

Advancements in drug delivery systems, such as the development of pen-injectors, have enhanced the usability and acceptance of Symlin among patients. These technological improvements contribute to market growth[1].

Competitive Landscape

The competitive landscape of the diabetes management market is intense, with several pharmaceutical companies vying for market share. AstraZeneca, the manufacturer of Symlin, faces competition from other diabetes medications and devices[4].

Financial Performance

Revenue and Growth Rate

AstraZeneca's financial performance indicates strong growth in the therapy areas relevant to Symlin. In 2023, the company reported total revenue of $45.8 billion, with a significant increase in revenue from the Cardiovascular, Renal & Metabolism segment, which includes diabetes treatments. Excluding COVID-19 medicines, the total revenue increased by 13% (15% at constant exchange rates)[2].

Regional Performance

The revenue from Symlin is distributed across various regions, with North America, Europe, and Asia-Pacific being key markets. In 2023, AstraZeneca reported a 6% increase in revenue in the US and a 10% increase in Europe, contributing to the overall growth of the Symlin market[2].

Market Trends and Drivers

Increasing Awareness and Diagnosis

Increased awareness and diagnosis of diabetes are driving the demand for Symlin. As healthcare systems improve, more patients are being diagnosed and treated, leading to higher sales of diabetes management medications[4].

Patient Compliance and Ease of Use

The development of user-friendly delivery systems, such as pen-injectors, has improved patient compliance. This ease of use is a significant driver for the adoption of Symlin[1].

ESG and Sustainability

Pharmaceutical companies, including AstraZeneca, are increasingly focusing on environmental, social, and governance (ESG) factors. AstraZeneca's commitment to reducing greenhouse gas emissions and improving access to healthcare programs positively impacts its market reputation and financial performance[2].

Challenges and Restraints

Regulatory Risks

The pharmaceutical industry is heavily regulated, and any changes in regulatory policies can impact the market negatively. Delays or rejections in regulatory approvals can hinder the growth of Symlin[3].

Competition from Alternative Treatments

The market for diabetes management is highly competitive, with various medications and devices available. Alternative treatments and new innovations can pose a threat to Symlin's market share[4].

Economic Factors

Economic fluctuations and changes in healthcare policies can affect the affordability and accessibility of Symlin. This can lead to variability in sales and revenue[3].

Future Outlook

The future outlook for Symlin is promising, driven by the growing demand for diabetes management solutions. Here are some key points:

Continued Growth

The market is expected to grow significantly from 2024 to 2031, driven by the increasing prevalence of diabetes and the need for effective management solutions[1][4].

Technological Innovations

Ongoing technological innovations in drug delivery systems and the development of new formulations are expected to enhance the market for Symlin[1].

Expanding Geographical Reach

AstraZeneca's global reach and diversified portfolio are expected to continue driving growth in various regions, including emerging markets[2].

Key Takeaways

• The Symlin market is growing rapidly due to the increasing prevalence of diabetes and the need for effective management solutions.
• The market is segmented by application and product type, with significant growth expected across various geographical regions.
• Regulatory approvals, technological advancements, and patient compliance are key drivers for the market.
• Despite challenges from regulatory risks and competition, the future outlook for Symlin remains positive.
• AstraZeneca's strong financial performance and commitment to ESG factors support the continued growth of Symlin.

FAQs

What is Symlin (pramlintide) used for?

Symlin (pramlintide) is an injectable medication used to manage blood sugar levels in patients with type 1 and type 2 diabetes.

Which company manufactures Symlin?

Symlin is manufactured by AstraZeneca.

What are the key segments of the Symlin market?

The Symlin market is segmented based on application (Type I Diabetes, Type II Diabetes) and product type (1.5ml Pen-injector, 2.7ml Pen-injector), as well as geographical regions.

What are the major drivers for the Symlin market?

The major drivers include the increasing prevalence of diabetes, technological advancements in drug delivery systems, and improved patient compliance.

What are the challenges facing the Symlin market?

The market faces challenges from regulatory risks, competition from alternative treatments, and economic factors affecting affordability and accessibility.

Sources

1. Market Research Intellect: Global Symlin Pramlintide Market Size And Forecast.
2. AstraZeneca: Annual Report and Form 20-F Information 2023.
3. Xeris Pharmaceuticals: 5,880,000 Shares Common Stock.
4. Cognitive Market Research: Symlin pramlintide Market Report 2024 (Global Edition).